EAN 2021 | Cell therapy in Huntington’s disease: where are we now?

Anne Rosser, PhD, FRCP, Cardiff University, Cardiff, UK, discusses the development of cell-based therapies for the treatment of Huntington’s disease. Cell therapies may provide a complementary therapeutic avenue to other treatment approaches. Up to now, a small number of clinical studies have investigated the transplantation of fetal cells. The largest fetal cell transplant trial to date, which was recently published, is the MIG-HD trial (NCT00190450). Prof. Rosser highlights the benefits and challenges of transplanting primary cells and notes that the availability of stem cell-derived donor cells is critical in the future and has the potential to change the field. This interview took place during the European Academy of Neurology 2021 congress.